Insights Center

Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.

Featured

Mintz Direct

On our new Mintz Direct page, Mintz thought leaders across industries and practice areas offer timely insights on developments that impact our clients and communities. Visit the Mintz Direct page to hear what our experienced attorneys and professionals are saying about what’s happening now.

Mintz Viewpoints

Use quotation marks to search for an exact phrase (e.g. “class action”)

Published

Showing 4345 - 4352 of 12140 results

Steps Your Company Should Consider Now to Protect Value with a Wave of Trade Secret Litigation on the Horizon Due to COVID-19 Pandemic, Economic Downturn, and Jobless Claims

April 17, 2020| Blog| Viewpoint

Mintz Partner Tapped to Help Get COVID-19 Relief Fund Up and Running

April 17, 2020| News

The NLRB's Final Joint-Employer Rule Will Soon Be In Effect

April 17, 2020| Blog| Viewpoint

State Securities Regulators Renew Warnings of COVID-19 Investment Scams

April 17, 2020| Blog| Viewpoint

Supreme Court Clarifies Race Discrimination Claims Under 42 U.S.C. § 1981 Must Meet More Stringent “But-For” Causation Standard

April 17, 2020| Blog| Viewpoint

ML Strategies COVID-19 Insights Week In Review — April 17, 2020

April 17, 2020| Article| Viewpoint

TCPA Litigation Update — Circuit Split Deepens on What Constitutes an ATDS Under the TCPA

April 16, 2020| Article| Viewpoint

TCPA Regulatory Update — Financial Institutions Seek Same Treatment as Healthcare Providers to Send COVID-19–Related Messages Without Prior Express Consent

April 16, 2020| Article| Viewpoint

News & Press Releases

Mintz Advises Charlesbank Capital Partners on Acquisition of Q6 Cyber

September 15, 2025

Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering

September 12, 2025

Mintz advised the underwriters in connection with a $285 million initial public offering by LB Pharmaceuticals Inc of 19,000,000 shares of common stock at an initial public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from this offering were approximately $285 million before deducting underwriting discounts and commissions and other offering expenses. In addition, LB Pharmaceuticals granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on September 11, 2025 under the ticker symbol “LBRX.”

Mintz Advises the Placement Agents in CAMP4’s up to $100 Million Private Placement

September 12, 2025

Mintz advised the placement agents in connection with CAMP4's up to $100 million private placement. The private placement included upfront gross proceeds of $50 million in exchange for common stock (and pre-funded warrants in lieu of common stock for certain investors). In addition, CAMP4 will be eligible to receive up to an additional $50 million in gross proceeds in exchange for common stock (and pre-funded warrants for certain investors), subject to achieving pre-specified milestones, including receipt of regulatory clearance to initiate a Phase 1/2 clinical trial in SYNGAP patients with its development candidate, CMP-SYNGAP-01.

View all News and Press Releases